“…In summary, PD-L1 TC expression seems to be a predictive biomarker for unresectable stage III NSCLC patients treated with cCRT and durvalumab ( 12 ). Patients with PD-L1 TC ≥50% may have the most durable and robust OS and PFS benefit from immune checkpoint inhibition consolidation.…”
PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab maintenance treatment. Transl Cancer Res 2023.
“…In summary, PD-L1 TC expression seems to be a predictive biomarker for unresectable stage III NSCLC patients treated with cCRT and durvalumab ( 12 ). Patients with PD-L1 TC ≥50% may have the most durable and robust OS and PFS benefit from immune checkpoint inhibition consolidation.…”
PD-L1 expression on tumor cells as a potential predictive biomarker for patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab maintenance treatment. Transl Cancer Res 2023.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.